Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2020 08:30 ET | Source: ARCA biopharma, Inc.

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or notAB201 is the only novel compound being developed for COVID Associated...
November 02, 2020 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarterTopline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02,...
October 07, 2020 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19

Initiation of Phase 2b clinical trial anticipated in Q4 2020Trial to enroll approximately 100 patients hospitalized with COVID-19Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 ...
October 05, 2020 16:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality

WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
September 21, 2020 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19

WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
August 05, 2020 16:15 ET | Source: ARCA biopharma, Inc.

Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update

AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...
July 07, 2020 08:30 ET | Source: ARCA biopharma, Inc.

SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators

Integrin A5 may be a new target for intervening in the cell infectious processFindings may lead to the development of precision therapeutic approaches to prevent SARS-CoV-2-cell entry while preserving...
June 03, 2020 09:55 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering

WESTMINSTER, Colo., June 03, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...
June 01, 2020 08:20 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces $9.4 Million Registered Direct Offering

WESTMINSTER, Colo., June 01, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) a late stage biopharmaceutical company applying a precision medicine approach to developing genetically...
May 28, 2020 08:00 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy

AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right